Darifenacin hydrobromide and C-reactive protein increased - a phase IV clinical study of FDA data

Summary:

C-reactive protein increased is reported as a side effect among people who take Darifenacin hydrobromide (darifenacin hydrobromide), especially for people who are female, 60+ old, also take Enbrel, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have C-reactive protein increased when taking Darifenacin hydrobromide. It is created by eHealthMe based on reports of 511 people who have side effects when taking Darifenacin hydrobromide from the FDA, and is updated regularly.

What is Darifenacin hydrobromide?

Darifenacin hydrobromide has active ingredients of darifenacin hydrobromide. eHealthMe is studying from 512 Darifenacin hydrobromide users. Check the latest studies of Darifenacin hydrobromide.

What is C-reactive protein increased?

C-reactive protein increased is found to be associated with 1,566 drugs and 2,281 conditions by eHealthMe. Check the latest studies of C-reactive protein increased.

On Jul, 20, 2026

511 people reported to have side effects when taking Darifenacin hydrobromide.
Among them, 75 people (14.68%) have C-reactive protein increased.

Could Darifenacin hydrobromide cause C-reactive protein increased?

Among these 75 people:

What is the gender of people who have C-reactive protein increased when taking Darifenacin hydrobromide? *

female: 95.24 %
male: 4.76 %

What is the age of people who have C-reactive protein increased when taking Darifenacin hydrobromide? *

What are other drugs people take besides Darifenacin hydrobromide? *

What are other side effects people have besides C-reactive protein increased? *

Drug Ineffective: 75 people, 100.00%
Herpes Zoster: 75 people, 100.00%
Pneumonia Viral: 62 people, 82.67%
Liver Function Test Abnormal: 62 people, 82.67%
Leukopenia (less number of white blood cells in blood): 62 people, 82.67%
Joint Pain: 62 people, 82.67%
Infection: 62 people, 82.67%
High Blood Cholesterol: 62 people, 82.67%
Fibromyalgia (a long-term condition which causes pain all over the body): 62 people, 82.67%
Drug Intolerance (drug sensitivity): 62 people, 82.67%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 75 people, 100.00%
Joint Pain: 32 people, 42.67%
Pain: 14 people, 18.67%
Sleep Disorder: 9 people, 12.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 4.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 2.67%

* Approximation only. Some reports may have incomplete information.

Do you take Darifenacin hydrobromide and have C-reactive protein increased?

- Check whether C-reactive protein increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Darifenacin hydrobromide:

Darifenacin hydrobromide (512 reports)

Browse all side effects of Darifenacin hydrobromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C-reactive protein increased:

C-reactive protein increased (1,566 drugs)

Browse all the conditions that are associated with C-reactive protein increased:

C-reactive protein increased (2,281 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on darifenacin hydrobromide (the active ingredients of Darifenacin hydrobromide) and Darifenacin hydrobromide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.